Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma-Reference-Cited by-同舟云学术

Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma

Published:2017-01 Issue:1 Volume:66 Page:106-115
ISSN:1323-8930
Container-title:Allergology International
language:en
Short-container-title:Allergology International

Author:

Odajima Hiroshi,Ebisawa Motohiro,Nagakura Toshikazu,Fujisawa Takao,Akasawa Akira,Ito Komei,Doi Satoru,Yamaguchi Koichi,Katsunuma Toshio,Kurihara Kazuyuki,Teramoto Takahide,Sugai Kazuko,Nambu Mitsuhiko,Hoshioka Akira,Yoshihara Shigemi,Sato Norio,Seko Noriko,Nishima Sankei

Funder

Novartis Pharma

Publisher

Elsevier BV

Subject

General Medicine,Immunology and Allergy

Reference44 articles.

1. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys;Rabe;J Allergy Clin Immunol,2004

2. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma;Chipps;J Allergy Clin Immunol,2007

3. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study

4. Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort;Chipps;Curr Respir Care Rep,2012

5. Nocturnal asthma in children affects school attendance, school performance, and parents' work attendance;Diette;Arch Pediatr Adolesc Med,2000

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers;Clinical Pharmacology in Drug Development;2024-02-22

2. Early Assessment of Efficacy and Safety of Biologics in Pediatric Allergic Diseases: Preliminary Results from a Prospective Real-World Study;Children;2024-01-28

3. Therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis;Frontiers in Allergy;2023-10-16

4. Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life;Journal of Personalized Medicine;2023-06-29

5. Physiologically‐Based Pharmacokinetic Modeling of Omalizumab to Predict the Pharmacokinetics and Pharmacodynamics in Pediatric Patients;Clinical Pharmacology & Therapeutics;2023-01-11